Cytomed Therapeutics Limited Stock Performance
| GDTC Stock | 2.96 0.47 13.70% |
CytoMed Therapeutics holds a performance score of 11 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.28, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning CytoMed Therapeutics are expected to decrease at a much lower rate. During the bear market, CytoMed Therapeutics is likely to outperform the market. Use CytoMed Therapeutics expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to analyze future returns on CytoMed Therapeutics.
Risk-Adjusted Performance
11 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in CytoMed Therapeutics Limited are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, CytoMed Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (13.70) | Five Day Return (10.03) | Year To Date Return (15.43) | Ten Year Return (26.00) | All Time Return (26.00) |
1 | CytoMed Therapeutics Stock Price Up 3.1 percent Whats Next | 10/11/2024 |
2 | CytoMed Therapeutics Launches First Patient Trial of Novel CAR-T Cancer Therapy GDTC Stock News - StockTitan | 11/20/2024 |
3 | CytoMed Therapeutics Leads 3 US Penny Stocks To Consider | 01/03/2025 |
| Begin Period Cash Flow | 1.2 M |
CytoMed |
CytoMed Therapeutics Relative Risk vs. Return Landscape
If you would invest 201.00 in CytoMed Therapeutics Limited on October 9, 2024 and sell it today you would earn a total of 142.00 from holding CytoMed Therapeutics Limited or generate 70.65% return on investment over 90 days. CytoMed Therapeutics Limited is currently generating 1.1143% in daily expected returns and assumes 7.4302% risk (volatility on return distribution) over the 90 days horizon. In different words, 66% of stocks are less volatile than CytoMed, and 78% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CytoMed Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CytoMed Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CytoMed Therapeutics Limited, and traders can use it to determine the average amount a CytoMed Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.15
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GDTC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.43 actual daily | 66 66% of assets are less volatile |
Expected Return
| 1.11 actual daily | 22 78% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average CytoMed Therapeutics is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CytoMed Therapeutics by adding it to a well-diversified portfolio.
CytoMed Therapeutics Fundamentals Growth
CytoMed Stock prices reflect investors' perceptions of the future prospects and financial health of CytoMed Therapeutics, and CytoMed Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CytoMed Stock performance.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (7.36) % | ||||
| Current Valuation | 35.17 M | ||||
| Shares Outstanding | 11.54 M | ||||
| Price To Book | 5.34 X | ||||
| Price To Sales | 88.41 X | ||||
| Revenue | 290.56 K | ||||
| Gross Profit | 355.19 K | ||||
| EBITDA | (2.94 M) | ||||
| Net Income | (3.13 M) | ||||
| Total Debt | 448.02 K | ||||
| Book Value Per Share | 0.88 X | ||||
| Cash Flow From Operations | (2.59 M) | ||||
| Earnings Per Share | (0.22) X | ||||
| Market Capitalization | 26.17 M | ||||
| Total Asset | 12.37 M | ||||
| Retained Earnings | (9.35 M) | ||||
| Working Capital | 9.38 M | ||||
About CytoMed Therapeutics Performance
By analyzing CytoMed Therapeutics' fundamental ratios, stakeholders can gain valuable insights into CytoMed Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CytoMed Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CytoMed Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 21.7 K | 23.5 K | |
| Return On Tangible Assets | (0.29) | (0.31) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.29) | (0.31) | |
| Return On Equity | (0.42) | (0.45) |
Things to note about CytoMed Therapeutics performance evaluation
Checking the ongoing alerts about CytoMed Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CytoMed Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CytoMed Therapeutics is way too risky over 90 days horizon | |
| CytoMed Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 290.56 K. Net Loss for the year was (3.13 M) with profit before overhead, payroll, taxes, and interest of 355.19 K. | |
| CytoMed Therapeutics generates negative cash flow from operations | |
| About 69.0% of the company shares are held by company insiders | |
| Latest headline from simplywall.st: CytoMed Therapeutics Leads 3 US Penny Stocks To Consider |
- Analyzing CytoMed Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CytoMed Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining CytoMed Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CytoMed Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CytoMed Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CytoMed Therapeutics' stock. These opinions can provide insight into CytoMed Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CytoMed Stock analysis
When running CytoMed Therapeutics' price analysis, check to measure CytoMed Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytoMed Therapeutics is operating at the current time. Most of CytoMed Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytoMed Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytoMed Therapeutics' price. Additionally, you may evaluate how the addition of CytoMed Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |